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Abstract Womenwith antiphospholipid antibodies (aPL) are at risk of adverse pregnancy outcomes,
including recurrent first-trimester pregnancy loss and late pregnancy complications such
as preeclampsia, HELLP (hemolysis, elevated liver enzyme levels, and low platelet levels)
syndrome, premature delivery, intrauterine growth restriction, placental abruption, and
intrauterine death. Current standard care in obstetric antiphospholipid syndrome includes
aspirin andheparin and has resulted in live-birth rates of approximately 70%.However, 30%
continue to have pregnancy complications. Hydroxychloroquine (HCQ) is suggested as a
new treatment approach, but no randomized controlled trials (RCTs) have assessed its
efficacy. This study aims to assess pregnancy outcome in women with aPL treated with
HCQ versus placebo in addition to standard treatment. The HYdroxychloroquine to
improve Pregnancy outcome in women with AnTIphospholipid Antibodies (HYPATIA)
study is a phase IV multicenter RCT, in which pregnant women with persistent aPL will
receive either HCQ or placebo in addition to their usual medication. The primary endpoint
is a compositeof aPL-relatedadversepregnancyoutcomes: oneormorepregnancy loss(es)
(either < 10 or > 10weeks of gestation) and premature birth before 34weeks due to any
of the following preeclampsia, eclampsia, or recognized features of placental insufficiency.
The HYPATIA study is expected to provide evidence on the effect of HCQ in pregnant
women with persistent aPL.
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Antiphospholipid syndrome (APS) is characterized by the
presence of persistent antiphospholipid antibodies (aPL) and
clinical manifestations such as thrombosis, microvascular
events, and/or pregnancy morbidity and mortality.1 The
obstetric morbidity in APS includes recurrent pregnancy
first-trimester loss, and aPL-related ischemic placental dys-
function such as preeclampsia, eclampsia, HELLP syndrome
(hemolysis, elevated liver enzyme levels, and low platelet
levels), premature delivery, intrauterine growth restriction,
along with intrauterine death.1 The aPL included in the
classification criteria include lupus anticoagulant, immuno-
globulin (Ig)G and IgM anticardiolipin antibodies (aCL), as
well as IgG and IgM anti-β2 glycoproteins I.1
The use of low-dose aspirin and low-molecular-weight
heparin (LMWH) is the current standard of prevention of
aPL-related obstetric complication in women with aPL, and
despite a limited bodyof evidence supporting this treatment,
approximately 70% of women deliver a live, viable infant.2–4
However, 30% of women with aPL continue to have aPL-
related pregnancy complications.
The prevention of obstetric complications of aPL, there-
fore, remains suboptimal, and other treatment options have
been explored. The addition of first-trimester low-dose
prednisolone to conventional treatment improved the rate
of live births in refractory aPL-related pregnancy loss(es) up
to 61%.5Other treatments, such as intravenous Ig, have failed
to show benefit.6,7 Hydroxychloroquine (HCQ) in APS is
receiving increasing international attention, and a group of
experts recommended HCQ in addition to standard treat-
ment in those with APS and with previous pregnancy failure
on current treatment.8 Furthermore, an international task
force highlighted the need for clinical trials of HCQ in
pregnant women with aPL and APS.9 Here, we will review
the available basic science and clinical evidence for using
HCQ in the setting of aPL. Moreover, we will present the
protocol for the first randomized controlled trial (RCT) of
HCQ versus placebo in pregnant women with persistent aPL.
What Is Known about HCQ’s Action in the
Presence of aPL: Basic Science
Chloroquine and HCQ are weakly basic 4-aminoquinoline
compounds. HCQ is the synthetic form of chloroquine and
differs only by a hydroxyl group attached to a side chain
resulting in a preserved efficacy with a less toxic side-effect
profile.10 The exact pharmacodynamics and action of HCQ in
vivo remain to be fully uncovered, but most likely multiple
molecular pathways are involved. HCQ’s detailed effects in
systemic lupus erythematosus (SLE) have been described
elsewhere.11 Wallace et al have described HCQ’s ability to
antagonize Toll-like receptor-mediated immune response
activation as one of the most important features in SLE.11
It remains unknown which effects of HCQ are important in
the immunomodulation of autoimmune diseases and also
if different effects are required in different autoimmune
diseases.12
In retrospective clinical studies, HCQ was associated with
a reduction in the risk of thrombosis in lupus patients and is
discussed below. The mechanism by which HCQ might have
an antithrombotic effect has been studied in a limitedway. In
vitro studies have shown that HCQ inhibits platelet aggrega-
tion and the release of arachidonic acid from aPL-induced
stimulated platelets.13 Furthermore, Rand et al showed that
aPL could disrupt the physiological anticoagulant shield of
annexin A5 (AnxA5), leading to exposure of procoagulant
phosphatidylserine and subsequently triggering thrombosis.
As a novel finding, the group could show that HCQ restores
the disruption of natural anticoagulant AnxA5 in patients
with aPL.14
Tissue factor (TF) is the key initiator of in vivo coagulation
and has been implicated in in the pathogenesis of APS.15 The
ability of aPL to induce TF expression was demonstrated in
vitro studies using serum samples from patients with pur-
ified aPL, whichwere added to cells, showing upregulation of
TF on monocytes,16,17 neutrophils,18 and endothelial cells.19
Several investigators have found that serum, plasma, purified
total IgG, antiB2GPI from APS patients increases TF expres-
sion and procoagulant activity on monocytes.20–22 López-
Pedrera et al showed that aCL IgG stimulates TF expression
on circulating monocytes, acting through intracellular path-
ways including NF-kappaB and MAP kinases.17 In mice with
aPL-induced fetal loss, neutrophils, in turn, can express TF
through aPL-induced complement activation.23
We have recently assessed the effect of using HCQ in
patients with aPL and APS on plasma biomarkers including
soluble TF, which has been shown to be increased in patients
with APS. (K.S., K.B., B.J.H., and Ms Kiran Parmar, Prof Jacob
Rand, MD, Dr. Wu, MD. The effect of treatment with hydro-
xychloroquine on biomarkers of hemostasis, complement,
inflammation and angiogenesis in patients with antipho-
spholipid antibodies and antiphosphlipid syndrome. Unpub-
lished Data, 2017). We showed that the use of HCQ was
effective to decrease soluble TF levels in patients with aPL
and APS 12 weeks after the commencement of HCQ com-
pared with baseline. This may be a mechanism contributing
HCQ’s antithrombotic effect.
Results from experiments in a murine model by Edwards
et al show that HCQ can reverse aPL-induced thrombosis.24
The group observed that aPL-injectedmice treatedwith HCQ
had a significantly reduced thrombus size, and that throm-
bus duration was reduced compared with mice treated with
placebo.24 In vitro studies showed that aPL are directly
pathogenic toward trophoblast cells, which is a mechanism
cited as a possible cause of recurrent first trimester preg-
nancy loss(es).25 In vitro studies have shown that HCQ
reversed the aPL-induced inhibition of the chemokine inter-
leukin 6 (IL-6).26 IL-6 released by first trimester trophoblast
cells had been shown to drive trophoblast migration (a vital
process for implantation) in previous studies by the same
group.27
We and others have hypothesized that angiogenic mole-
cules may play a role in the pathogenesis of obstetric APS, in
light of their role in other placental dysfunction conditions
such as preeclampsia.28,29 Elevated level of circulating solu-
ble fms-like tyrosine kinase 1 (sFlt1) is thought to cause the
maternal expression of preeclampsia. Levels of sFlt1 and
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proangiogenic factors (such as vascular endothelial growth
factor and placental growth factor [PlGF]) have been pro-
posed as predictors of preeclampsia in healthy women.28,29
In 492 pregnant women from the prospective multicenter
cohort, the PROMISSE cohort (PRedictors of pRegnancy out-
come: BioMarkers In antiphospholipid Syndrome and Sys-
temic lupus Erythematosus), Kim et al found that the
circulating pro- and anti-angiogenic factors such as sFlt1,
PlGF, and soluble endoglin (sEng) measured between week
12 and 15 of gestation were predictive of adverse pregnancy
outcomes in women with SLE and aPL.30
Currently, available evidence suggests that aPL can affect
the maternal side of developing placenta by reacting with
endometrial cells in the decidua, by which they induce a
proinflammatory phenotype and interfere with the physio-
logical implantation process causing first-trimester loss.31
These mechanisms are also thought to play a role in the
failure of adequate vascularization of developing placenta,
ultimately resulting in complications such as preeclampsia.
Wewished to explore the possible beneficial effect of HCQ on
angiogenic biomarkers, as this has not been explored before.
Some studies support the hypothesis that the comple-
ment system is activated and plays a role in the pathogenesis
of thrombotic and obstetric APS.23,32–35 Our group and
others have previously confirmed complement activation
in patients with isolated aPL and APS (thrombotic and
obstetric APS) compared with healthy controls.36,37 Our
most recent in vivo results assessing the effect of HCQ on
complement activation markers C3-des-Arg and Bb in HCQ
naive, non-pregnant aPL and APS patients at baseline and 12
weeks after the commencement of HCQ did not show any
significant change in these values.
In mice exposed to complement inhibitors and knockout
mice which have complement deficiencies, there is inhibi-
tion of fetal loss and growth restrictionmediated by aPL,23,32
and also less aPL-induced thrombus.33,34 Bertolaccini et al
showed a possible protective effect HCQ of in a model of aPL-
induced fetal loss.38 In their mousemodel, the fetuses died in
50% of pregnant aPL-injected mice, and the survivors were
growth-restricted and with smaller placentas compared
with control mice. The administration of HCQ to mice
exposed to aPL prevented fetal death, increased placental
and fetal weight and decreased placental superoxide produc-
tion (amarker of oxidative stress).38 Also, the group reported
HCQ-induced complement inhibition in APS patient serum,
specifically looking at the common pathway complement
activation product C5a-des-Arg after receiving 6.5 mg/kg
HCQ for 6 months.38
At an intracellular level, in vitro studies show that aPLs
can induce endosomal NADPH (NOX) in endothelial cells
and monocytes.39,40 NOX is an enzyme complex involved in
proinflammatory signaling pathways.12 Müller-Calleja et al
recently published first in vitro data suggesting that
HCQ significantly reduces the induction of endosomal
NOX, which leads to a reduction of downstream gene activa-
tion.12 This “protective” mechanism of HCQ in preventing
monocyte activation was confirmed in mice injected with
human aPL.12
What Is Known about HCQ’s Use in Patients
with Systemic Lupus Erythematosus and
APS: Clinical Studies
HCQ is traditionally an antimalarial drug and has since the
1950s been widely used in the treatment of patients with
rheumatoid arthritis or systemic connective tissue diseases
such as SLE. HCQ is amongst the four drugs currently licensed
for the treatment of SLE (other drugs licensed for SLE include
aspirin, corticosteroids, and belimumab).41 The efficacy of
HCQ in patients with SLE has been well described. A cohort
study of 150 SLE patients showed that it improves damage
free survival,42 whereas data of 518 SLE patients from the
observational LUMINA cohort showed that its use is asso-
ciatedwith a reduced accrual of newdisease damage.43 Ruiz-
Irastorza performed a prospective observational cohort of
232 patients, showing an improved survival in SLE patients
taking HCQ.44 The use of HCQ in SLE is also associated with a
reduced risk of SLE flares. The Canadian Hydroxychloroquine
Study Group reported from their RCT, that discontinuation of
HCQ was associated with a 2.5 relative risk of a clinical
lupus flare and that the risk of severe disease flare was
significantly higher in patientswho hadHCQ discontinued.45
The antithrombotic effects of HCQ in patients with SLE
were reported in data from the LUMINA cohort. In univariate
analysis, including 442 SLE patients with aPL of whom 46
were identified having 51 recorded thrombotic events (over
1,446 visits followed over a mean of 88months), a protective
effect of HCQ use was demonstrated (odds ratio [OR], 0.536).
This finding is in line with an observational prospective
cohort study of 232 SLE patients, in which Cox regression
analysis showed that HCQ use was associatedwith a reduced
risk thrombosis (seven events occurred while patients were
taking HCQ, seven further events happened after the patient
had stopped HCQ whereas 28 events were reported in
patients who had never taken HCQ, so yielding a hazard
ratio of 0.28).44 Likewise, the antithrombotic effect of HCQ
could also be demonstrated in several other cohort, case–
control, and retrospective studies.11 Moreover, the safe use
of HCQ in pregnancy and lactation has been extensively
documented and systematically reviewed.46–48 Most data
on the use of HCQ in pregnancy stems frompatientswith SLE.
Treatment of pregnant patients with SLE was first described
more than three decades ago, and national and international
clinical guidelines now recommend using HCQ in pregnant
women with underlying autoimmune diseases requiring
immunomodulation.49,50
The role of HCQ in APS is currently being investigated in
thrombotic and obstetric APS. In a prospective nonrando-
mized study of 40 patients with primary thrombotic APS
without underlying SLE, Schmidt-Tanguy et al studied the
effect of 400 mgHCQ in addition to oral anticoagulationwith
vitamin K antagonists, target international normalized ratio
2 to 3. None of the patients receiving HCQ along with
standard anticoagulation had recurrent thromboembolic
events, whereas 30% in the control group experienced a
recurrent event (p ¼ 0.0086).51 Unfortunately, the first
RCT assessing the role of HCQ role as primary prophylaxis
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in aPL-positive patients has recently been terminated due to
manufacturing shortage.52
In retrospective studies of pregnant patients with aPL and
or APS, we and others showed that HCQ is a candidate for
preventing aPL-related adverse pregnancy outcomes.53,54 In
a retrospective multicenter cohort consisting of 30 APS
patients (and 35 pregnancies), Mekinian et al reported that
HCQ was associated with fewer first trimester miscarriages
(pregnancy losses decreased from 81 to 19%, p < 0.05) and
improved live birth rates in refractory obstetric APS to 78%
(p < 0.05).53 In our retrospective observational cohort study
of 96 women with 170 pregnancies, we also showed that
HCQ treatment was associated with a higher rate of live
births (67% in HCQ treated vs. 57% in untreated patients,
p ¼ 0.05) and a lower prevalence of pregnancy morbidity
(47 vs. 63%, p ¼ 0.004). Pregnancy duration was longer in
patients receiving HCQ compared with those who did not
receive HCQ (median 27.6 weeks, range [6–40] vs. 21.5 weeks,
range [6–40]; p ¼ 0.03) and fetal losses beyond 10 weeks of
gestationwere less frequent inwomenwhowere treatedwith
HCQ (2 vs. 11%, p ¼ 0.05). Moreover, ischemic placental-
mediated complications (preeclampsia, eclampsia, and fetal
growth restrictionwere less prevalent in HCQ-treatedwomen
than in the control group (2 vs. 10.9%, p ¼ 0.05). There was a
significantly higher rate of women undergoing spontaneous
vaginal labor in HCQ women compared with women without
HCQ treatment (37.3 vs. 14.3%, p ¼ 0.01). The association of
HCQ with the absence of aPL-related complications in preg-
nancy was confirmed in multivariate analysis (OR, 2.2; 95%
confidence interval, 1.2–136.1; p ¼ 0.04).54 However, the de-
sign of this retrospective study was suboptimal, as the two
groups were heterogeneous, with a higher prevalence of SLE
amongst those receiving HCQ. These clinical and animal
studies, as well as in vitro and ex vivo data, suggest a potential
role of HCQ in reducing pregnancy morbidity and mortality
in women with aPL. Given all of the available evidence, we
proposed HYPATIA study (HYdroxychloroquine to improve
Pregnancy outcome in women with AnTIphospholipid Anti-
bodies) which is a randomized controlled multicenter trial of
HCQ versus placebo in women with persistent aPL planning
for pregnancy. Our hypothesis is that HCQ may improve
aPL-related pregnancy complications.55
Methods
Study Design
The HYPATIA study is an investigator-initiated multicenter,
double-blind RCT of women with persistent aPL planning to
conceive. Patients will be randomized to HCQ or an identi-
cally looking placebo in addition to their usual medication.
Once awoman is enrolled into the HYPATIA study, shewill
be attending 3 monthly follow-up visits until she conceives
(defined as prepregnancy visits). Patients will be starting to
take the investigational medicinal product (IMP) as soon as
theyare randomized (i.e., before conception). If no pregnancy
is achieved within 12 months, she will be excluded from the
study. Study visits coincide with the usual routine follow-up
visits. On these visits, the IMP will repeatedly be dispensed,
and compliance will be assessed. All data will be collected in
an electronic case record file.
When awoman conceives, shewill contact the study team
and attend her first pregnancy visit (first-trimester visit).
At this visit, a new trialmedicationwill be dispensed. Follow-
up visits for the HYPATIA study purpose will be scheduled
once every trimester (defined as 1st, 2nd, and 3rd-trimester
visits). Nevertheless, if the participant required closer mon-
itoring, she will be followed up accordingly as per standard
of care.Womenwill be instructed to stop trial medication on
the day of delivery and will be asked to hand in the rest of
the trial medication at their postpartum follow-up. The
postpartum visit shall be completed 6 weeks postpartum.
Patient Recruitment
Potentially eligible women will be identified in routine out-
patient clinics in our participating sites, which include: Guy’s
and St Thomas’ NHS Foundation Trust, London, United
Kingdom; Imperial College Health Care NHS Trust, London,
United Kingdom;University College LondonNHS Foundation
Trust, London, United Kingdom; LiverpoolWomen’s Hospital
NHS Foundation Trust; Oxford University Hospitals NHS
Foundation Trust, Oxford, United Kingdom; Academic
Medical Center Amsterdam, the Netherlands; University
Hospital Torino, Italy; University Hospital Copenhagen,
Denmark. Patients will receive full information about the
HYPATIA study, and if they decide to take part, a written
informed consent will be obtained. Patients will have as
much time as they need to consider their participation.
Provided all eligibility criteria are fulfilled, study randomiza-
tion can be undertaken, and the IMP will be dispensed.
Potential participants will be identified by their physician
during routine outpatient visits to the trial sites. The
HYPATIA study visit assessment schedule is outlined in
►Fig. 1.
Inclusion Criteria
1. Women with known persistent aPL (i.e., isolated persis-
tent aPL or APS) who are planning pregnancy and consent
to participate
Exclusion Criteria
1. Women who are already pregnant
2. Allergy or adverse event to HCQ. Hypersensitivity to the
active substance, 4-aminoquinoline or any of the com-
pounds of the IMP or placebo
3. Current treatment with HCQ
4. Age < 18 and > 45 years
5. Body weight < 45 kg
6. Psoriasis
7. Uncontrolled epilepsy
8. Anti-Ro antibodies
9. Renal replacement therapy
10. Other severe active comorbidities (human immunodefi-
ciency virus, hepatitis B)
11. Porphyria
12. History of retinopathy
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13. History of galactose intolerance, lactase deficiency, or
glucose-galactose malabsorption
14. Participation in any other IMP trial at the time of consent
15. Previous pregnancy failure on HCQ
Laboratory assessment for aPL diagnosis: For the purpose of
the HYPATIA study aPL positivity is defined by the presence
of a positive test for anticardiolipin antibodies (IgG/IgM
isotypes > 95th percentile) and/or lupus anticoagulant
Fig. 1 The HYPATIA study visit assessment schedule. HYPATIA, HYdroxychloroquine to Improve Pregnancy Outcome in Women with
AnTIphospholipid Antibodies.
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and/or anti-β2-glycoprotein-I (IgG/IgM isotypes > 95th per-
centile), on two or more consecutive occasions more than
12 weeks apart. All participating sites will be expected to
have established their own 95th percentile, and data on
absolute values (for aCL and anti-β2-glycoprotein-I), lower
and upper normal value will be collected in the electronic
database. aPL are assessed according to standard established
methods.56,57
Duration of Trial
The HYPATIA study will last for a total of 36 months, which
includes recruitment and follow-up of patients. The end of
the trial is defined as database lock. Each individual will
remain in the study as long as their time to conception (up to
maximum 12 months), their full length of pregnancy until
delivery. In total 328 pregnant women (sample size calcula-
tion is detailed below) will be included in the study. The trial
flow chart is summarized in ►Fig. 2.
Primary Outcome Measures
The primary endpoint is a composite of three principal
aPL-related adverse pregnancy outcomes: one or more
pregnancy loss(es) (either < 10 weeks gestation or beyond
10 weeks of gestation of a morphologically normal fetus
documented by ultrasound or by direct examination of
the fetus) and premature birth of a morphologically
normal neonate before 34 weeks due to any of pree-
clampsia, eclampsia, and recognized features of placental
insufficiency.
Premature birth for other reasons will not be included.
The components of the primary endpoint will each be
presented as secondary endpoints (below).
Secondary Outcomes Measures
The predefined secondary endpoints include: (1) Pregnancy
loss < 10 weeks gestation, (2) pregnancy loss > 10th week
of gestation of a morphologically normal fetus documented
by ultrasound or by direct examination of the fetus,
(3) premature birth of a morphologically normal neonate
< 34 weeks due to any of preeclampsia, eclampsia, recog-
nized features of placental insufficiency, (4) gestational age
at delivery, (5) birth weight, (6) cesarean delivery, (7) Apgar
score < 7 at 5 minutes, (8) neonatal morbidity (bleeding or
thrombotic complications, infections, congenital abnormal-
ities), (9) days to hospital discharge following delivery
(mother and child), (10) thrombotic events in the mother
during pregnancy and 6 weeks postpartum, and (11) days of
the neonate in special care.
Suspected unexpected serious adverse reactions and
other serious adverse events (SAEs) will be reported to the
regulatory authorities and the research ethics committees, as
appropriate. All SAE reports received from the study siteswill
be reviewed by independent medically qualified staff.
SAEs that do not require reporting: Pregnancy itself is well
known to potentially causing nausea and tiredness due to
several physiological adjustments of the body especially in
thefirst trimester. Any symptoms thought to be related to the
physiological changes in pregnancy do not require reporting.
Fig. 2 The HYPATIA study trial flow chart. HYPATIA, HYdroxychloroquine to Improve Pregnancy Outcome in Women with AnTIphospholipid
Antibodies.
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In patients with aPL, we expect pregnancy complications.
Therefore, aPL-related pregnancy complications, such as mis-
carriage < 10 weeks’ gestation, miscarriage > weeks 10, pre-
mature birth < 34 weeks due to preeclampsia, eclampsia or
fetal growth restriction, and stillbirth shall not be reported as
SAE. For these eventswehave designed a special section in the
electronic database “adverse pregnancy outcomes,” which
shall be completed in this case. Any other adverse events
will be reported.
Randomization
Randomization will be performed by an independent indi-
vidual at King’s Clinical Trials Unit (King’s CTU), using a
computer-based minimization process, adjusting for throm-
bosis (yes/no), previous adverse pregnancy outcomes (yes/
no), and previous pregnancy (yes/no).
The investigators and trial subjects will remain blinded to
treatment. The trial pharmacist will be blinded too. Unique
pack numbers for the trial medication will be generated for
the active and placebo products and will be sent with
randomization emails. The trial statistician will know only
A versus B, with the meaning of A and B held by King's CTU.
Statistical Analysis
Sample Size
The sample size was calculated based on our audit data.
Retrospective data from St Thomas’ Hospital showed that
treatment with HCQwas associatedwith a higher rate of live
birth (67% in women with SLE and aPL treated with HCQ vs.
57% in women in the control group p ¼ 0.05) and a lower
prevalence of aPL-related pregnancy morbidity (47 vs. 63%
p ¼ 0.004).8 The trial is powered to detect a 16% reduction in
pregnancy morbidity, which is the main outcome of the
study (total sample size 328). Aminimumof 328womenwill,
therefore, be randomized. The calculation was made on
the following: significance α ¼ 0.05, power 1  β 80%, and
percentage cross 5%.
Primary statistical analysis: Percentages in both arms of
the study will be compared using binomial regression with
a log link, adjusting for the minimization variables to give
risk ratios. Risk differences will be estimated similarly.
Continuous measures will be compared using linear regres-
sion adjusting for minimization variables and baseline mea-
surement of the outcome (where available). Estimateswill be
given with 95% confidence intervals.
Results will be considered significant at the 5% level.
However, attention will be paid to the totality of results
and the exact size of the p value. Smaller values will be
treated as stronger evidence against the null hypothesis. The
intention-to-treat principle will be followed in the main
analysis, but a secondary per-protocol analysis will also be
performed toprovide additional information on the nature of
the treatment effect.
Three subgroup analyses are planned: by the previous
thrombosis; previous adverse pregnancy outcomes; pre-
vious pregnancy. In each case, the primary outcome will
be analyzed in each subgroup, and an interaction test per-
formed for evidence of a difference in treatment effect
between the groups.
No formal interim analyses are planned. The Data Mon-
itoring Committee will aim to meet in person at least every
6 months and will consider the results so far. They are
empowered to request that the trial stops if there is over-
whelming evidence for or against one treatment, such that to
randomize further patients would be unethical.
Competent authority approval in the United Kingdom has
passed the initial assessment and ethics approval is currently
awaited. As a European multicenter trial, we are following
the “voluntary harmonization procedure.”58
Discussion
We hypothesize that the addition of HCQ to the standard-of-
care treatment in pregnant women with aPL will improve
aPL-related adverse pregnancy outcomes. Current data to
suggest a role of HCQ in these patients is inadequate; hence,
we have designed an adequately powered RCT.53,54
We have shown that with a rigorously applied local
protocol around 70% of pregnant women with aPL/APS will
deliver a viable infant.2 The current management includes
LMWH and/or low-dose aspirin. As mentioned above, this
does not prevent all maternal, fetal, and neonatal complica-
tions. Our retrospective study suggests that HCQ has a
beneficial effect in women with aPL, as the treatment with
HCQ was associated with a higher rate of live births (67 vs.
57%, p ¼ 0.05) and a lower prevalence of aPL-related preg-
nancy morbidity (47 vs. 63%, p ¼ 0.004).54 Despite the
heterogeneity in the two groups in terms of SLE prevalence
and previous pregnancy history, our results support the
concept that women with aPL may benefit from treatment
with HCQ during pregnancy to improve pregnancy outcome.
We have also conducted a systematic review of the
evidence of HCQ in obstetric APS, which confirmed a lack
of evidence.8 We, therefore, performed an expert-based
clinical judgment consensus, which is an accepted approach
to address a specific and clinically relevant question in an
area were best clinical practice is uncertain. The experts
agreed that HCQ could be considered in selected cases of
patients with obstetric APS or after the failure of standard
treatment with aspirin and any heparin-based agent. More-
over, the majority of experts considered adding HCQ in
specific scenarios, such as womenwith previous thrombosis
or previous ischemic placental medicated complications.8
The ideal RCT to answer the question of the benefit of HCQ
in pregnancy in those with aPL would be to investigate
women with refractory obstetric APS, that is, those who
have failed conventional treatment, and then to randomize
this group to HCQ versus placebo. However, after reviewing
our patient group anddiscussingwith all our trial centers, we
calculated that it would take 10 years to recruit adequate
women to a study of this design. We have hence chosen to
study women with aPL rather than women with refractory
obstetric APS because it not only practically feasible but
also supported by the results of our previous retrospective
study.
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Some may argue that that the inclusion of women with
aPL above the 95th percentile as opposed to the defined 99th
percentile in the Miyakis criteria is a fault in the study.1
However, it is our and others experience, that low-level aPL
are highly relevant in the setting of obstetric APS.59,60 This is
in linewith the observation of Ruffatti et al, that womenwith
purely obstetric APS have lower aCL antibody titers com-
paredwith patients with thrombotic APS.61Moreover, retro-
spective data and data from a cohort study suggest that low-
titer aCL, defined as those between the 95th and 99th
percentiles, are still of clinical significance for women with
obstetric APS.62,63
Although this study includes women planning to con-
ceives, andwill, therefore, be perceived by some as a difficult
study. However, some of our HYPATIA study team members
have experience in successfully conducting RCTs in which
women were recruited preconceptionally.64 We are invol-
ving centers that are expert tertiary centers for managing
women with aPL and managing them preconception and
throughout pregnancy. Recruitment estimates of some
patients that will be entered into the study have been
obtained from each center and exceed the proposed number
by approximately 20%, and we fully expect completion of
the study in the allotted time.
HYPATIA is thefirst trial to randomizeHCQ versus placebo
in pregnant women with persistent aPL, and our results will
provide an evidence-base for the decision to use of HCQ in
these patients.
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